OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press14910.17650/1818-8346-2015-10-3-10-17HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯThe multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myelomaМногоцентровый опыт применения бендамустина в лечении рецидивных и рефрактерных форм множественной миеломыVoloshinS. V.ВолошинСергей Владимирович
Russian Federation

16, 2nd Sovetskaya St., St. Petersburg, 191024

191024, Санкт-Петербург, ул. 2-я Советская, 16

servolos@gmail.comBessmeltsevS. S.БессмельцевС. С.
Russian Federation

16, 2nd Sovetskaya St., St. Petersburg, 191024

191024, Санкт-Петербург, ул. 2-я Советская, 16

ZagoskinaT. P.ЗагоскинаТ. П.
Russian Federation

72 Krasnoarmeyskaya St., Kirov, 610027

610027, Киров, ул. Красноармейская, 72

MedvedevaN. V.МедведеваН. В.
Russian Federation

3 Dinamo St., St. Petersburg, 197110

197110, Санкт-Петербург, просп. Динамо, 3

KaplanovK. D.КаплановК. Д.
Russian Federation

78 Zemlyachki St., Volgograd, 400138

400138, Волгоград, ул. Землячки, 78

KaryaginaE. V.КарягинаЕ. В.
Russian Federation

4 Avangardnaya St., St. Petersburg, 198205

198205, Санкт-Петербург, ул. Авангардная, 4

GarifullinA. D.ГарифуллинА. Д.
Russian Federation

16, 2nd Sovetskaya St., St. Petersburg, 191024

191024, Санкт-Петербург, ул. 2-я Советская, 16

KuvshinovA. Yu.КувшиновА. Ю.
Russian Federation

16, 2nd Sovetskaya St., St. Petersburg, 191024

191024, Санкт-Петербург, ул. 2-я Советская, 16

StelmashenkoL. V.СтельмашенкоЛ. В.
Russian Federation

16, 2nd Sovetskaya St., St. Petersburg, 191024

191024, Санкт-Петербург, ул. 2-я Советская, 16

AbdulkadyrovK. M.АбдулкадыровК. М.
Russian Federation

16, 2nd Sovetskaya St., St. Petersburg, 191024

191024, Санкт-Петербург, ул. 2-я Советская, 16

Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological AgencyФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства»Kirov Institute of Hematology and Transfusiology, Federal Medical and Biological AgencyФГБУН «Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства»City Clinical Hospital № 31СПб ГБУЗ «Городская клиническая больница № 31»Volgograd Regional Clinical Oncology Dispensary № 1ГБУЗ «Волгоградский областной клинический онкологический диспансер № 1»City Hospital № 15СПб ГБУЗ «Городская больница № 15»0810201510310170710201507102015https://oncohematology.abvpress.ru/ongm/article/view/149

Relapsed and refractory (R/R) multiple myeloma (MM) constitutes a specific and unmet medical need. Median survival ranges from as little as 6 to 9 months, and responses to treatment are characteristically short. In patients with R/R MM after therapy of bortezomib and/or immunomodulators a bendamustine-based treatment can be used as “salvage”.

In this retrospective analysis we have identified 32 patients with R/R MM by means of case research, have been bendamustine-based treated at Hematological Clinics of Russian Federation since 2011. Median age was 67 (43–81) years, the female/male ratio was 2.5:1. After in median 2 (1–7) lines of prior therapy patients received in median 3 (1–9) cycles of bendamustine-based therapy. Bendamustine dosage was 70–120 mg/m2 /day on 2 days of each 28-day cycle until progressive disease or intolerability. Overall rate response was 56.2 %: 21.9 % partial response, stable disease 34.4 %. Median time to progression was 5.3 (0.8–18.0) months and median overall survival was 25.4 (0.8–47.1) months. Hematologic toxicity was in 53.2 % of patients.

multiple myelomabendamustinebortezomiblenalidomidestem cells transplantationgenetic abnormalitiesмножественная миеломабендамустинбортезомибленалидомидтрансплантация гемопоэтических стволовых клетокгенетические аномалии1. Gentile M., Recchia A.G., Mazzoneetal C. et al. Perspectives in the treatment of multiple myeloma. Expert Opin Biol Ther 2013;13(1):1–22.Gentile M., Recchia A.G., Mazzoneetal C. et al. Perspectives in the treatment of multiple myeloma. Expert Opin Biol Ther 2013;13(1):1–22.2. Бессмельцев С.С., Стельмашенко Л.В., Карягина Е.В. и др. Бортезомиб (Велкейд) в индукционной терапии множественной миеломы. Клиническая онкогематология 2008;1(4):315–22. [Bessmeltsev S.S., Stelmashenko L.V., Kariagina E.V. et al. Bortezomib (Velcade) for initial treatment of multiple myeloma. Klinicheskaya onkogematologiya = Clinical Oncohematology 2008;1(4):315–22. (In Russ.)].Бессмельцев С.С., Стельмашенко Л.В., Карягина Е.В. и др. Бортезомиб (Велкейд) в индукционной терапии множественной миеломы. Клиническая онкогематология 2008;1(4):315–22. [Bessmeltsev S.S., Stelmashenko L.V., Kariagina E.V. et al. Bortezomib (Velcade) for initial treatment of multiple myeloma. Klinicheskaya onkogematologiya = Clinical Oncohematology 2008;1(4):315–22. (In Russ.)].3. Kristinsson S.Y., Landgren O., Dickman P.W. et al. Patterns of survival in multiple myeloma: a population based study of patients diagnosed in Sweden. J Clin Oncol 2007;25:1993–9.Kristinsson S.Y., Landgren O., Dickman P.W. et al. Patterns of survival in multiple myeloma: a population based study of patients diagnosed in Sweden. J Clin Oncol 2007;25:1993–9.4. Бессмельцев С.С., Стельмашенко Л.В., Карягина Е.В и др. Лечение пожилых пациентов с множественной миеломой на современном этапе. Онкогематология 2010;4:6–13. [Bessmeltsev S.S., Stelmashenko L.V., Kariagina E.V. et al. Modern strategies in therapy of elderly patients with multiple myelomа. Onkogematologiya = Oncohematology 2010;4:6–13. (In Russ.)].Бессмельцев С.С., Стельмашенко Л.В., Карягина Е.В и др. Лечение пожилых пациентов с множественной миеломой на современном этапе. Онкогематология 2010;4:6–13. [Bessmeltsev S.S., Stelmashenko L.V., Kariagina E.V. et al. Modern strategies in therapy of elderly patients with multiple myelomа. Onkogematologiya = Oncohematology 2010;4:6–13. (In Russ.)].5. Pocock N. Bendamustine for the fourthline treatment of multiple myeloma. London cancer new drugs group rapid review, 2013. 7 p.Pocock N. Bendamustine for the fourthline treatment of multiple myeloma. London cancer new drugs group rapid review, 2013. 7 p.6. Kalaycio M. Clinical experience with Bendamustine: A new treatment for patients with chronic lymphocytic leukemia. Clin Leukemia 2008;2(4):223–9.Kalaycio M. Clinical experience with Bendamustine: A new treatment for patients with chronic lymphocytic leukemia. Clin Leukemia 2008;2(4):223–9.7. Lorenzo L. The Alkylating Properties of Bendamustine. Clin Adv Hematol Oncol 2011;9(8):3–5.Lorenzo L. The Alkylating Properties of Bendamustine. Clin Adv Hematol Oncol 2011;9(8):3–5.8. Knop S., Straka C., Haen M. et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after highdose chemotherapy. Haematologica 2005;90:1287–8.Knop S., Straka C., Haen M. et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after highdose chemotherapy. Haematologica 2005;90:1287–8.9. Michael M., Bruns I., Bölke E. et al. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 2010;15(1):13–9.Michael M., Bruns I., Bölke E. et al. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 2010;15(1):13–9.10. Ponisch W., Bourgeois M., Moll B. et al. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 2012;139:499–508.Ponisch W., Bourgeois M., Moll B. et al. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 2012;139:499–508.11. Heinz L., Hedwig K., Clemens L. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 2014;123(7):985–91.Heinz L., Hedwig K., Clemens L. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 2014;123(7):985–91.12. Rodon P., Hulin C., Pegourie B. et al. Bendamustine, bortezomib, anddexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myélome (IFM) 2009-01 protocol. J Clin Oncol 2012;30;аbstr 8014.Rodon P., Hulin C., Pegourie B. et al. Bendamustine, bortezomib, anddexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myélome (IFM) 2009-01 protocol. J Clin Oncol 2012;30;аbstr 8014.13. http://grls.rosminzdrav.ru/ImgInstr.aspx?folder=ScanVavilova &Filepath=\Ne_trebuet_vnesenia\Net_ND_IZM\437575\IP_IZM&idReg=38926&isOld=1&fileType=jpg&pfolder=2.http://grls.rosminzdrav.ru/ImgInstr.aspx?folder=ScanVavilova &Filepath=Ne_trebuet_vneseniaNet_ND_IZM437575IP_IZM&idReg=38926&isOld=1&fileType=jpg&pfolder=2.14. Абдулкадыров К.М., Волошин С.В., Шмидт А.В., Шуваев В.А. Эффективность бортезомиба при лечении больных рецидивирующей и рефрактерной множественной миеломой (анализ российских данных исследования eVOBS). Гематология и трансфузиология 2012;57(3): 22–5. [Abdulkadyrov K.M., Voloshin S.V., Schmidt A.V., Shuvaev V.A. Bortezomib efficiency in patients with relapsing and refractory multiple myeloma (analysis of the Russian data of EVOBS). Gematologiya i transfuziologiya = Hematology and Transfusiology 2012;57(3):22–5. (In Russ.)].Абдулкадыров К.М., Волошин С.В., Шмидт А.В., Шуваев В.А. Эффективность бортезомиба при лечении больных рецидивирующей и рефрактерной множественной миеломой (анализ российских данных исследования eVOBS). Гематология и трансфузиология 2012;57(3): 22–5. [Abdulkadyrov K.M., Voloshin S.V., Schmidt A.V., Shuvaev V.A. Bortezomib efficiency in patients with relapsing and refractory multiple myeloma (analysis of the Russian data of EVOBS). Gematologiya i transfuziologiya = Hematology and Transfusiology 2012;57(3):22–5. (In Russ.)].15. Mikhael J.R., Dingli D., Roy V. et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc 2013;88(7):360–76.Mikhael J.R., Dingli D., Roy V. et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc 2013;88(7):360–76.16. Волошин С.В., Шмидт А.В., Гарифуллин А.Д. и др. Бендамустин в лечении рецидивирующей/рефрактерной множественной миеломы. Гематология и трансфузиология 2014;59(1):83. [Voloshin S.V., Schmidt A.V., Garifullin A.D. et al. Bendamustine in treatment of relapsed and refractory multiple myeloma. Gematologiya i transfuziologiya = Hematology and Transfusiology 2014;59(1):83. (In Russ.)].Волошин С.В., Шмидт А.В., Гарифуллин А.Д. и др. Бендамустин в лечении рецидивирующей/рефрактерной множественной миеломы. Гематология и трансфузиология 2014;59(1):83. [Voloshin S.V., Schmidt A.V., Garifullin A.D. et al. Bendamustine in treatment of relapsed and refractory multiple myeloma. Gematologiya i transfuziologiya = Hematology and Transfusiology 2014;59(1):83. (In Russ.)].17. Damaj G., Malard F., Hulin C. et al. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma 2012;53(4):632–4.Damaj G., Malard F., Hulin C. et al. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma 2012;53(4):632–4.18. Ludwig H., Kasparu H., Leitgeb C. et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 2014;123(7):985–91.Ludwig H., Kasparu H., Leitgeb C. et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 2014;123(7):985–91.19. Lentzsch S., O'Sullivan A., Kennedy R.C. et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012;119(20):4608–13.Lentzsch S., O'Sullivan A., Kennedy R.C. et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012;119(20):4608–13.20. Durie B.G.M., Harousseau J.L., Miguel J.S. et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–73.Durie B.G.M., Harousseau J.L., Miguel J.S. et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–73.21. Ponisch W., Wiesler J., Leibleinetal S. et al. Successful mobilization of peripheral blood stem cells after intensive bendamustine pretreatment in patients with multiple myeloma. Blood 2010;116;аbstr 4439.Ponisch W., Wiesler J., Leibleinetal S. et al. Successful mobilization of peripheral blood stem cells after intensive bendamustine pretreatment in patients with multiple myeloma. Blood 2010;116;аbstr 4439.22. Грицаев С.В., Кузяева А.А., Волошин С.В. и др. Заготовка трансплантата для аутологичной трансплантации гемопоэтических стволовых клеток онкогематологическим больным: частота и причины неудачных сборов. РМЖ. Приложение. Онкология 2013;4(1):30–5. [Gritsaev S.V., Kuzyaeva А.А., Voloshin S.V. et al. Separation of transplant for autologous stem cells transplantation by oncohematological patients: frequency and reasons of unsuccessful collecting. RMJ. Appendix. Oncologiya = Oncology 2013;4(1): 30–5. (In Russ.)].Грицаев С.В., Кузяева А.А., Волошин С.В. и др. Заготовка трансплантата для аутологичной трансплантации гемопоэтических стволовых клеток онкогематологическим больным: частота и причины неудачных сборов. РМЖ. Приложение. Онкология 2013;4(1):30–5. [Gritsaev S.V., Kuzyaeva А.А., Voloshin S.V. et al. Separation of transplant for autologous stem cells transplantation by oncohematological patients: frequency and reasons of unsuccessful collecting. RMJ. Appendix. Oncologiya = Oncology 2013;4(1): 30–5. (In Russ.)].23. Savarese D.M.F. Common terminology criteria for adverse events. Version 4.0. National Cancer Institute, 2009. 194 p.Savarese D.M.F. Common terminology criteria for adverse events. Version 4.0. National Cancer Institute, 2009. 194 p.